Sterilization Monitoring and Assurance Leaders Unite Crosstex Acquires SPSmedical
Sterilization Monitoring and Assurance Leaders Unite Crosstex Acquires SPSmedical Hauppauge, New York MN — November 1, 2012 — Crosstex International, a subsidiary of Cantel Medical Corp. (NYSE CMN) announces the acquisition of SPSmedical — a move that unites two of
Sterilization Monitoring and Assurance Leaders Unite Crosstex Acquires SPSmedical
Hauppauge, New York MN — November 1, 2012 — Crosstex International, a subsidiary of Cantel Medical Corp. (NYSE: CMN) announces the acquisition of SPSmedical — a move that unites two of the leading North American providers of sterilization monitoring services and sterility assurance products in dental, acute-care, alternate-care and office based practitioner markets.
The addition of SPSmedical to the Crosstex family strengthens the Crosstex position in the acute-care and alternate-care markets while broadening the Crosstex sterility assurance product offering. Based in Rochester, NY, SPS is a leading manufacturer and provider of biological and chemical indicators for sterility assurance monitoring services and products. SPS offers a wide-array of products and services that enable hospitals, surgi-centers, office-based practitioners and dental offices to safely and accurately monitor and verify their sterilization practices and protocols.
According to Gary Steinberg, President & CEO of Crosstex, “SPSmedical is the perfect complement to our ConFirm brand biologic monitoring business and will provide us with the platform to broaden our reach into the acute-care and alternate-care markets. SPS’ strong leadership in defining and establishing sterility assurance standards in healthcare settings is a strong platform upon which Crosstex can expand its global presence as a leader in the healthcare infection prevention and control market.”
“The addition of SPS to the Crosstex family expands our presence in the acute-care and alternate-care markets, broadens our product portfolio and strengthens our position in the dental market,” said Andrew Whitehead, Senior Vice President of Business Development. “Utilizing the strengths, reputations and talent of the combined Crosstex and SPS teams, we will increase our market penetration into all healthcare channels, both domestically and internationally.”
For information on the full line of Crosstex infection control and preventive products, please contact Crosstex at 1.631.582.6777 or visit us on the web at www.crosstex.com
